Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
Argentine Registry of Inflammatory Myopathies
Dermatomyositis
Idiopathic inflammatory myopathy
Inflammatory myopathies
Myositis-specific antibodies
Polymyositis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
18
01
2021
accepted:
25
05
2021
revised:
04
05
2021
pubmed:
24
6
2021
medline:
21
10
2021
entrez:
23
6
2021
Statut:
ppublish
Résumé
To describe clinical features in patients with inflammatory myopathies (IMs) from the Argentine Registry of Inflammatory Myopathies, and their relationship with myositis-specific antibodies (MSAs). This cross-sectional study included 360 adult patients with dermatomyositis (DM), polymyositis (PM), and inclusion body myositis. Demographics, clinical, and serological characteristics were retrospectively recorded (2016-2019). MSAs were determined by immunoblotting. Patients who were positive for anti-Jo-1, Mi-2, and MDA5 were compared against a group of patients, taken as reference group, who were negative for all MSAs. Women 72%, median age at diagnosis was 47.3 years (18-82). The most frequent subtypes were DM (43.9%) followed by PM (30%).The most frequent MSAs were anti-Jo-1 (51/317), 16.1%; MDA5 (12/111), 10.8%, and Mi-2 (23/226), 10.2%. Anti-Jo-1 was associated (p < 0.05) with a higher frequency of chronic disease course, interstitial lung disease (ILD), arthritis, and mechanic's hands. Anti-Mi-2 was found in patients who had higher frequency of skin manifestations and higher CK values (p < 0.001). Patients with anti-MDA5 had normal or low CK levels. Anti-MDA5 was associated (p < 0.05) with skin manifestations, arthritis, and ILD. The rest of MSAs had frequencies lower than 8%. Anti-TIF1ϒ was found in eight DM patients and one had cancer. Anti-SRP was found in seven patients who had PM and elevated CK. Anti-Jo-1 was the most frequent MSA, and was associated with ILD; MDA5 was associated with CADM and ILD, and Mi-2, with classical DM. Despite the different prevalence with respect to other cohorts, the clinical characteristics for each MSA group were similar to the data reported in other studies. Key Points • This study describes the prevalence of MSAs in the Argentine Registry of IMs. • Anti-Jo-1 and anti-MDA5 were associated with ILD. • Anti-Mi-2 was the third most frequent MSA, associated with classical DM.
Identifiants
pubmed: 34159491
doi: 10.1007/s10067-021-05797-2
pii: 10.1007/s10067-021-05797-2
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4473-4483Informations de copyright
© 2021. International League of Associations for Rheumatology (ILAR).
Références
Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J (2014) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatol (United Kingdom) 54(1):50–63
Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol [Internet]. 2018;14(5):255–68. Available from: https://doi.org/10.1038/nrrheum.2018.48
Li S, Ge Y, Yang H, Wang T, Zheng X, Peng Q, et al. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Clin Rheumatol. 2019;38(8).
Lundberg IE, Svensson J (2013) Registries in idiopathic inflammatory myopathies. Curr Opin Rheumatol 25(6):729–734
doi: 10.1097/01.bor.0000434667.55020.e1
Anthony Bohan, M.D., and James B.Peter. P. The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF OTAGO on January 7, 2015. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights reserved. N Engl J Med. 1975;292(7):344–7.
Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open [Internet]. 2017; 3(2):e000507. Available from: https://doi.org/10.1136/rmdopen-2017-000507
Tawil R, Griggs RC (2002) Inclusion body myositis. Curr Opin Rheumatol 14(6):653–657
doi: 10.1097/00002281-200211000-00004
Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest [Internet]. 2010;138(6):1464–74. Available from: https://doi.org/10.1378/chest.10-0180
Concha JSS, Tarazi M, Kushner CJ, Gaffney RG, Werth VP (2019) The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria. Br J Dermatol 180(5):1001–1008
doi: 10.1111/bjd.17536
Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, Abadi I, Caeiro F AA and A-S. The GLADEL multinational Latin American Prospective inception cohort of 1,214 patients with systemic lupus erythematosus-ethnic and disease heterogeneity among “Hispanics”. Med.2004;83:1–17.
Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG et al (2019) Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol 38(1):125–132
doi: 10.1007/s10067-018-4267-z
Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77(1).
Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramírez R, Jara LJ, Saavedra MA, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther. 2013;15(2).
Tiniakou E, Mammen AL (2017) Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 52(1):20–33
doi: 10.1007/s12016-015-8511-x
Vilela VS, Prieto-González S, Milisenda JC, Selva-O´Callaghan A, Grau JM. Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up. Rheumatol Int. 2015;35(5):915–2014
Gomez G, Gargiulo M, Granel A y Col. Métodos de diagnóstico en el estudio de las Miopatías Inflamatorias Autoinmunes. Datos del Registro Argentino de Miopatías Inflamatorias de la Sociedad Argentina de Reumatología. Rev Argent Reumatol. 2020;1.
Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol [Internet]. 2017;52(1):1–19. Available from: https://doi.org/10.1007/s12016-015-8510-y
Gonzalez-bello Y, Ortiz-Villalvazo MA, Garcia-Valladares I, Navarro-Zarza JE, Andrade-Ortega L, Nava-Zavala A. Study of Autoantibodies in a cohort of Mexican patients with idiopathic inflammatory myopathies. 55(Dm):17–9.
Cruellas MG, Viana VS, Levy-Neto M, Souza FH, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo) 68:909–914
Brouwer R, Hengstman GJD, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60(2):116–123
doi: 10.1136/ard.60.2.116
Mammen AL (2016) Autoimmune myopathies. Contin Lifelong Learn Neurol 22(6):1852–1870
doi: 10.1212/01.CON.0000511070.50715.ab
Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJL, Franceschini F et al (2015) Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study. Med (United States) 94(32):1–7
Chinoy H, Adimulam S, Marriage F, New P, Vincze M, Zilahi E et al (2012) Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis 71(6):961–965
doi: 10.1136/annrheumdis-2011-200182
Li J, Liu Y, Li Y, Li F, Wang K, Pan W et al (2018) Associations between anti-melanoma differentiation associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis. J Dermatol 45(1):46–52
doi: 10.1111/1346-8138.14092
Sato Y, Otsuka K, Tamai K, Ono Y, Hamaguchi Y, Tomii K (2017) An atypical clinical course of anti-MDA5 antibody positive interstitial lung disease in a patient with three deteriorations in 9 years. Intern Med 56:341–346. https://doi.org/10.2169/internalmedicine.56.6856
Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147(4):391–398
doi: 10.1001/archdermatol.2011.52
Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R (2017) Antimelanoma differentiation associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol 44(3):319–325
doi: 10.3899/jrheum.160682
Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K et al (2018 Jul) Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Respir Med 1(140):1–5
doi: 10.1016/j.rmed.2018.05.010
Dos Passos Carvalho MIC, Shinjo SK (2019) Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis. Adv Rheumatol (London, England) 59(1):27
doi: 10.1186/s42358-019-0071-y
Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW (2003) Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 48(8):2285–2293
doi: 10.1002/art.11090
Love LA, Weinberg CR, Mc Connaughey DR, Oddis CV, Medsger TA, Reveille JD et al (2009) Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 60(8):2499–2504
doi: 10.1002/art.24702
Srivastava P, Dwivedi S, Misra R (2016) Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int 36(7):935–943
doi: 10.1007/s00296-016-3494-3
Targoff IN, Reichlin M (1985) The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 28(7):796–803
doi: 10.1002/art.1780280711
Masiak A, Kulczycka J, Czuszyńska Z, Zdrojewski Z (2016) Clinical characteristics of patients with anti- TIF1-γ antibodies. Reumatologia 54(1):14–18
doi: 10.5114/reum.2016.58756
Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik J, Danoff SK et al (2017) Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res 69(2):263–270
doi: 10.1002/acr.22920
Wang L, Liu L, Hao H, Gao F, Liu X, Wang Z et al (2014) Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 24(4):335–341
doi: 10.1016/j.nmd.2014.01.002
Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K et al (2016) Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87(10):1038–1044
doi: 10.1136/jnnp-2016-313166
Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Vol. 20, Current Rheumatology Reports. 2018.
Thiébaut M, Terrier B, Menacer S, Berezne A, Bussone G, Goulvestre C et al (2013) Antisignal recognition particle antibodies-related cardiomyopathy. Circulation 127(5):434–436
doi: 10.1161/CIRCULATIONAHA.112.118877
Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P. Bench to bedside review of myositis autoantibodies. Clin Mol Allergy [Internet]. 2018;16(1):1–17. Available from: https://doi.org/10.1186/s12948-018-0084-9
Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman D et al (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73(1):227–232. https://doi.org/10.1136/annrheumdis-2012-201800
Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllosi L, Dankó K (2014) Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 13(12):1211–1219
doi: 10.1016/j.autrev.2014.08.011
Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods [Internet]. 2012;384(1–2):128–34. Available from: https://doi.org/10.1016/j.jim.2012.07.019
Zhong L, Yu Z, Song H. Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: a meta-analysis of 20 cohorts. Clin Immunol [Internet]. 2019;198:11–8. Available from: https://doi.org/10.1016/j.clim.2018.11.008